On August 13, Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released new data from its Phase 1b/2a RESOLVE trial showing that odynophagia, the medical term for painful swallowing, faded dramatically in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results